Hepatitis B. Chronic viral hepatitis B without delta-agent
Conditions
Interventions
Intervention 1: Intervention group: Group A: Patients who received the coincided combination of tenofovir (300 mg/day) and Peg- IFNa (180 mcg/week) for 48 weeks. Intervention 2: Intervention group: Gr
Sponsors
vice presidency for siences and technology , Iran national silences foundation
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients with the age of 18-65 years Negative Hepatitis B e antigen at baseline Quantifiable serum hepatitis B viral DNA load> 2000 IU/ml At least six months from the initial diagnosis Those with no history of receiving an antiviral drug
Exclusion criteria
Exclusion criteria: Hepatitis C, D and HIV Viruses co-infection Dialysis patients with renal impairment Severe liver diseases History of previous hepatitis B treatment (for at least 30 days) Other liver comorbidities such as Autoimmune Hepatitis Hepatocellular Carcinoma, uncompensated cirrhosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The final end-points were rate of HBV DNA loss<20 IU/ml at week 48. Timepoint: HBV DNA load Will be measured. in the Twelve, Twenty-four, thirty-six and 48 weeks for all patients. Method of measurement: by using of Cobas TaqMan polymerase chain reaction (Roche Diagnostics Basel, Switzerland) by Keyvan Virology Specialty Laboratory (KVSL). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShahram Agah
Iran University of Medical Sciences
Outcome results
None listed